Related Experiment Video
Updated: Jan 10, 2026

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
Published on: October 8, 2015
Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-Analysis
Matthew Dankner1,2,3, Laurie-Rose Dubé1, Mark Sorin1,2
1Faculty of Medicine, McGill University, Montreal, QC H3A 0G4, Canada.
BRAF V600E mutations in early-stage colon cancer (CC) are linked to worse survival outcomes. This finding is crucial for refining treatment strategies and clinical trial designs for patients with BRAF V600E CC.
Area of Science:
- Oncology
- Genetics
- Clinical Research
Background:
- BRAF mutations occur in 10% of colon cancers (CCs), correlating with poor prognosis in metastatic disease.
- BRAF V600E status predicts response to targeted therapies like cetuximab + encorafenib in metastatic CC.
- Emerging trials investigate BRAF inhibitors for early-stage CC, necessitating an understanding of BRAF V600E's impact in this setting.
Purpose of the Study:
- To characterize the clinical outcomes of early-stage BRAF V600E colon cancer.
- To evaluate the prognostic significance of BRAF V600E mutations in stage 2/3 CC.
- To inform the design of clinical trials for early-stage BRAF V600E CC.
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials.
- Inclusion criteria: Stage 2/3 BRAF V600E colon cancer.
- Co-primary endpoints: Overall survival (OS) and disease-free survival (DFS); random-effects model used.
Main Results:
- BRAF V600E was associated with significantly inferior OS (HR 1.49) and DFS (HR 1.17) compared to BRAF wild-type (WT).
- These findings persisted in patients with microsatellite instability-low/stable or proficient mismatch repair.
- Analysis included six RCTs with 6836 (WT) and 843 (BRAF V600E) patients.
Conclusions:
- BRAF V600E confers an inferior prognosis in early-stage colon cancer compared to BRAF WT.
- Understanding these outcomes is vital for optimizing future clinical trial designs for this patient subgroup.
More Related Videos
08:18Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer Survival Analysis
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Targeted Cancer Therapies
There are several types of targeted therapies against...